原发性胆汁性肝硬化预后与治疗监测  

Prognostic prediction of primary biliary cirrhosis and therapy monitoring with ursodeoxycholic acid

作　　者：梁艳[1] 杨再兴[1] 仲人前[1] 周琳[1] 

机构地区：[1]第二军医大学附属长征医院实验诊断科,上海200003

出　　处：《中华检验医学杂志》2016年第2期82-84,共3页Chinese Journal of Laboratory Medicine

基　　金：国家自然科学基金（81571591）;上海市浦江人才计划项目（15PJD004）

摘　　要：原发性胆汁性肝硬化（PBC）是慢性胆汁淤积性自身免疫性肝病，熊去氧胆酸（UDCA）是治疗的一线药物。目前国际上有多个标准用于预测PBC患者预后和疗效判断，指导患者的个体化医疗。本文阐释了近年来常用的PBC预后评估方法及其在UDCA治疗监测中的应用，并展望面临的挑战和今后的研究方向。Primary biliary cirrhosis （PBC） is a chronic cholestie autoimmune liver disease and ursodeoxyeholic acid （UDCA） is the first-line drug for the treatment. Currently there are several standards applied for the prognostic and therapeutic predictions of PBC, as well as for the guidance of personalized treatment. This paper elucidated the prognostic predicting factors in PBC and their applications in therapy monitoring with UDCA. Current challenges and future research interests are also put forward.

关 键 词：肝硬化 胆汁性 熊脱氧胆酸 预后 治疗结果 疾病严重程度指数 

分 类 号：R575.2[医药卫生—消化系统]